Etavopivat

Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1 January 2026 to 31 March 2026 Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US. Q1 2026 adjusted sales, excluding the 340B provision reversal, decreased by 4% at CER, driven by lower realised prices, partly offset by GLP-1 volume growth across geographies. Q1 2026 adjusted Obesity care sales increased by 22% at CER. US Operations adjusted sales decreased by 11% at CER in Q1 2026, driven by lower realised prices, partly offset by volume growth across the Wegovy ® product portfolio. International Operations sales increased by 6% at CER in Q1 2026, driven by higher volumes. Q1 2026 adjusted operating profit decreased by 6% at CER, while reported operating profit increased by 65% at CER, driven by a provision reversal related to the 340B Drug Pricing Program in the US. Commercial highlights Wegovy ® pill was launched in the US on 5 January 2026, and for the week ending 17 April, total weekly prescriptions exceeded 200,000. Coupled with total prescriptions for Q1 2026 of around 1.3 million and now more than 2 million since launch, it marks the strongest-ever GLP-1 volume launch in the US. Q1 2026 sales for Wegovy ® pill reached DKK 2,256 million, impacted by pre-launch pipeline fill with wholesalers and telehealth partners. Pending regulatory decisions, the first Wegovy ® pill launches outside the US are expected during the second half of 2026. Pipeline progress Within obesity, Wegovy ® HD (injectable semaglutide 7.2 mg) was approved by the FDA in March and subsequently launched in the US on 7 April. In the STEP UP trial, Wegovy ® HD provided 20.7% mean weight loss. Within obesity, the zenagamtide AMAZE phase 3 programme was initiated. Within diabetes, Awiqli ® , the first-ever once-weekly basal insulin for type 2 diabetes, was approved by the FDA. In sickle cell disease, etavopivat successfully met both co-primary endpoints in the HIBISCUS phase 3 trial. Outlook The 2026 outlook is raised, driven by increased expectations for GLP-1 product sales. Adjusted sales growth for 2026, which excludes the 340B provision reversal, is now expected to be -4 to -12% at CER. Adjusted operating profit growth, also excluding the 340B provision reversal, is now expected to be -4 to -12% at CER. PROFIT AND LOSS DKK million Q1 2026 Growth in DKK Growth at CER Net sales 96,823 24% 32% Operating profit 59,618 54% 65% Adjusted net sales 1 70,063 (10%) (4%) Adjusted operating profit 1 32,858 (15%) (6%) CER: Constant exchange rates; 1 Excl. USD 4.2 billion non-recurring impact from a provision reversal related to the 340B Drug Pricing Program in the US. Further details in Appendix 7 “Wegovy ® is driving a strong start to 2026 for Novo Nordisk, led by the rapid adoption of Wegovy ® pill - the most efficacious GLP-1 tablet now used by more than one million patients since its January launch. As the global momentum behind peptide-based therapies accelerates, Wegovy ® pill is defining a novel category as the only oral peptide for the treatment of obesity, setting a new benchmark for what patients and physicians can expect. The strong Wegovy ® performance, combined with continued growth in International Operations, has led us to raise our 2026 guidance for both adjusted sales and adjusted operating profit,” said Mike Doustdar, president and CEO of Novo Nordisk. “During the quarter, we also secured multiple approvals for Wegovy ® HD, strengthening the Wegovy ® portfolio, and enabling patients to achieve nearly 21% weight loss.” On 6 May 2026 at 13.00 CEST, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors' (the contents of the company's website do not form a part of this Form 6-K). A bout Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 usmediarelations@novonordisk.com Investors: Michael Novod +45 3075 6050 nvno@novonordisk.com Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com Max Ung +45 3077 6414 mxun@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com Alex Bruce +45 3444 2613 axeu@novonordisk.com Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com Company announcement No 30 / 2026 Attachment CA260506- Q1-2026

Novo Nordisk said Monday that its sickle cell disease pill succeeded in a late-stage study. However, the data came in behind expectations the company set last year. Etavopivat cut the occurrence of the painful sickle cell complications known as vaso-occlusive crises (VOCs) by 27% compared with placebo, hitting one of the trial’s co-primary endpoints. However, the company’s then-head of rare disease Ludovic Helfgott told Endpoints News last year that Novo was hoping to see a 50% cut. Nonetheless, Novo intends to file the drug with regulators later this year. The 27% reduction in the annualized rate of VOCs in the Phase 3 part of the HIBISCUS program appears to be a drop in effectiveness from what etavopivat, a pyruvate kinase activator, showed in the Phase 2 portion of the same study. There, it cut the rate of VOCs by 46%. Comparing the results isn’t strictly a fair comparison. The Phase 3 data were event-driven, meaning a certain number of VOCs had to accrue before the data could be analyzed. In the Phase 2 portion, the investigators simply counted the VOCs that occurred after a year of treatment. However, in March 2025, Helfgott said that a 50% cut would have been “broadly in line” with what was seen in the Phase 2 portion. Jefferies analysts were upbeat on the data, writing in a Monday note that the results “come as a positive surprise” given recent disappointments in this disease. A couple of treatments for sickle cell have run into difficulties: Pfizer pulled its sickle cell drug Oxbryta worldwide in 2024 over safety concerns, and Europe and the UK rescinded approval of Novartis’ sickle cell therapy Adakveo, citing an unfavorable “benefit-risk balance.” But the analysts also warned that regulators might prefer to wait for data from another trial of etavopivat before making an approval decision. The ongoing Phase 3b HIBSICUS-2 study could report data next year. The Monday data also showed that a daily 400 mg etavopivat pill produced better hemoglobin responses than placebo, meeting the Phase 3 portion’s other co-primary endpoint. Of the patients given etavopivat, 48.7% had an increase in hemoglobin response of at least 1g/dL after 24 weeks, versus 7.2% on placebo. This corresponds to an adjusted rate difference of 41.2%, Novo said. The company also said the drug also delayed the occurrence of the first VOC event compared with placebo. The median time to first VOC was 38.4 weeks with etavopivat, versus 20.9 weeks with placebo. Patients in the trial also received standard of care as background therapy. The drug appeared to be well-tolerated, Novo said. Novo obtained etavopivat via its purchase of the drug’s originator, Forma Therapeutics, for $1.1 billion in 2022. The content above comes from the network. if any infringement, please contact us to modify.